Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer

Prostate cancer usually presents with early-stage disease, yet a significant proportion of patients present or will progress to androgen-independent, nonmetastatic prostate cancer (AIPC). Chemotherapy has demonstrated statistically significant improvements in palliation of AIPC. Docetaxel in particu...

Full description

Saved in:
Bibliographic Details
Published in:Reviews in urology 2003, Vol.5 Suppl 3 (Suppl 3), p.S65-S70
Main Authors: Leonard, Gregory D, Dahut, William L, Gulley, James L, Arlen, Philip M, Figg, William D
Format: Article
Language:English
Subjects:
Optimizing Treatment for Advanced Prostate Cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page S70
container_issue Suppl 3
container_start_page S65
container_title Reviews in urology
container_volume 5 Suppl 3
creator Leonard, Gregory D
Dahut, William L
Gulley, James L
Arlen, Philip M
Figg, William D
description Prostate cancer usually presents with early-stage disease, yet a significant proportion of patients present or will progress to androgen-independent, nonmetastatic prostate cancer (AIPC). Chemotherapy has demonstrated statistically significant improvements in palliation of AIPC. Docetaxel in particular has demonstrated high response rates as a single agent. Thalidomide is effective in treating many malignancies, including prostate cancer. Thalidomide may act synergistically with docetaxel through their antiangiogenic effects. We performed a phase II trial of docetaxel with or without thalidomide in patients with AIPC and demonstrated encouraging response rates with combination therapy. We advocate further investigation of this promising combination regimen.
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1502338</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734110806</sourcerecordid><originalsourceid>FETCH-LOGICAL-p1108-bc25b47b57c42617a9120767da8a422aa02e6f6e7fe64c3bd4321d922f26c29d3</originalsourceid><addsrcrecordid>eNpVkE9LxDAQxXtQ3HX1K0huXiw0f5q0F0FWXYUFL3ou02S6G2mTmmRFv71dXEUvMwPv8XuPOcrmtGQ8l1TSWXYa42tRCC6q-iSbUVlXZV3yeba99RoTfGBPwBmSttBb4wdrkEAkQFJASAO6RPyYrHek82HvDH6DLifWGRxxGi5dEefdMLFigmQ1GYPfX0g0OI3hLDvuoI94ftiL7OX-7nn5kK-fVo_Lm3U-UlpUeatZ2QrVlkoLJqmCmrJCSWWgAsEYQMFQdhJVh1Jo3hrBGTU1Yx2TmtWGL7Lrb-64awc0emoWoG_GYAcIn40H2_xXnN02G__e0LJgnFcT4PIACP5thzE1g40a-x4c-l1sFBf7poWcnBd_o34zfr7LvwDiMXf2</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734110806</pqid></control><display><type>article</type><title>Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer</title><source>PubMed Central(OpenAccess)</source><creator>Leonard, Gregory D ; Dahut, William L ; Gulley, James L ; Arlen, Philip M ; Figg, William D</creator><creatorcontrib>Leonard, Gregory D ; Dahut, William L ; Gulley, James L ; Arlen, Philip M ; Figg, William D</creatorcontrib><description>Prostate cancer usually presents with early-stage disease, yet a significant proportion of patients present or will progress to androgen-independent, nonmetastatic prostate cancer (AIPC). Chemotherapy has demonstrated statistically significant improvements in palliation of AIPC. Docetaxel in particular has demonstrated high response rates as a single agent. Thalidomide is effective in treating many malignancies, including prostate cancer. Thalidomide may act synergistically with docetaxel through their antiangiogenic effects. We performed a phase II trial of docetaxel with or without thalidomide in patients with AIPC and demonstrated encouraging response rates with combination therapy. We advocate further investigation of this promising combination regimen.</description><identifier>ISSN: 1523-6161</identifier><identifier>PMID: 16985953</identifier><language>eng</language><publisher>United States: MedReviews, LLC</publisher><subject>Optimizing Treatment for Advanced Prostate Cancer</subject><ispartof>Reviews in urology, 2003, Vol.5 Suppl 3 (Suppl 3), p.S65-S70</ispartof><rights>2003 MedReviews, LLC 2003 MedReviews, LLC</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1502338/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1502338/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16985953$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leonard, Gregory D</creatorcontrib><creatorcontrib>Dahut, William L</creatorcontrib><creatorcontrib>Gulley, James L</creatorcontrib><creatorcontrib>Arlen, Philip M</creatorcontrib><creatorcontrib>Figg, William D</creatorcontrib><title>Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer</title><title>Reviews in urology</title><addtitle>Rev Urol</addtitle><description>Prostate cancer usually presents with early-stage disease, yet a significant proportion of patients present or will progress to androgen-independent, nonmetastatic prostate cancer (AIPC). Chemotherapy has demonstrated statistically significant improvements in palliation of AIPC. Docetaxel in particular has demonstrated high response rates as a single agent. Thalidomide is effective in treating many malignancies, including prostate cancer. Thalidomide may act synergistically with docetaxel through their antiangiogenic effects. We performed a phase II trial of docetaxel with or without thalidomide in patients with AIPC and demonstrated encouraging response rates with combination therapy. We advocate further investigation of this promising combination regimen.</description><subject>Optimizing Treatment for Advanced Prostate Cancer</subject><issn>1523-6161</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNpVkE9LxDAQxXtQ3HX1K0huXiw0f5q0F0FWXYUFL3ou02S6G2mTmmRFv71dXEUvMwPv8XuPOcrmtGQ8l1TSWXYa42tRCC6q-iSbUVlXZV3yeba99RoTfGBPwBmSttBb4wdrkEAkQFJASAO6RPyYrHek82HvDH6DLifWGRxxGi5dEefdMLFigmQ1GYPfX0g0OI3hLDvuoI94ftiL7OX-7nn5kK-fVo_Lm3U-UlpUeatZ2QrVlkoLJqmCmrJCSWWgAsEYQMFQdhJVh1Jo3hrBGTU1Yx2TmtWGL7Lrb-64awc0emoWoG_GYAcIn40H2_xXnN02G__e0LJgnFcT4PIACP5thzE1g40a-x4c-l1sFBf7poWcnBd_o34zfr7LvwDiMXf2</recordid><startdate>2003</startdate><enddate>2003</enddate><creator>Leonard, Gregory D</creator><creator>Dahut, William L</creator><creator>Gulley, James L</creator><creator>Arlen, Philip M</creator><creator>Figg, William D</creator><general>MedReviews, LLC</general><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2003</creationdate><title>Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer</title><author>Leonard, Gregory D ; Dahut, William L ; Gulley, James L ; Arlen, Philip M ; Figg, William D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p1108-bc25b47b57c42617a9120767da8a422aa02e6f6e7fe64c3bd4321d922f26c29d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Optimizing Treatment for Advanced Prostate Cancer</topic><toplevel>online_resources</toplevel><creatorcontrib>Leonard, Gregory D</creatorcontrib><creatorcontrib>Dahut, William L</creatorcontrib><creatorcontrib>Gulley, James L</creatorcontrib><creatorcontrib>Arlen, Philip M</creatorcontrib><creatorcontrib>Figg, William D</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Reviews in urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leonard, Gregory D</au><au>Dahut, William L</au><au>Gulley, James L</au><au>Arlen, Philip M</au><au>Figg, William D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer</atitle><jtitle>Reviews in urology</jtitle><addtitle>Rev Urol</addtitle><date>2003</date><risdate>2003</risdate><volume>5 Suppl 3</volume><issue>Suppl 3</issue><spage>S65</spage><epage>S70</epage><pages>S65-S70</pages><issn>1523-6161</issn><abstract>Prostate cancer usually presents with early-stage disease, yet a significant proportion of patients present or will progress to androgen-independent, nonmetastatic prostate cancer (AIPC). Chemotherapy has demonstrated statistically significant improvements in palliation of AIPC. Docetaxel in particular has demonstrated high response rates as a single agent. Thalidomide is effective in treating many malignancies, including prostate cancer. Thalidomide may act synergistically with docetaxel through their antiangiogenic effects. We performed a phase II trial of docetaxel with or without thalidomide in patients with AIPC and demonstrated encouraging response rates with combination therapy. We advocate further investigation of this promising combination regimen.</abstract><cop>United States</cop><pub>MedReviews, LLC</pub><pmid>16985953</pmid></addata></record>
fulltext fulltext
identifier ISSN: 1523-6161
ispartof Reviews in urology, 2003, Vol.5 Suppl 3 (Suppl 3), p.S65-S70
issn 1523-6161
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1502338
source PubMed Central(OpenAccess)
subjects Optimizing Treatment for Advanced Prostate Cancer
title Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T00%3A48%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Docetaxel%20and%20thalidomide%20as%20a%20treatment%20option%20for%20androgen-%20independent,%20nonmetastatic%20prostate%20cancer&rft.jtitle=Reviews%20in%20urology&rft.au=Leonard,%20Gregory%20D&rft.date=2003&rft.volume=5%20Suppl%203&rft.issue=Suppl%203&rft.spage=S65&rft.epage=S70&rft.pages=S65-S70&rft.issn=1523-6161&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E734110806%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p1108-bc25b47b57c42617a9120767da8a422aa02e6f6e7fe64c3bd4321d922f26c29d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=734110806&rft_id=info:pmid/16985953&rfr_iscdi=true